etcembly | news

Etcembly's TCR therapeutics featured in Forbes

AI expert and futurist Bernard Marr has written about Etcembly's innovative generative AI approach to developing TCR-based cancer...

88 views

Etcembly reveals world’s first AI generative bispecific T cell engager with picomolar affinity

Techbio innovator Etcembly reveals world’s first generative AI-designed bispecific T cell engager with picomolar affinity.

1,588 views

Etcembly's T-cell engager featured in Inside Precision Medicine

The announcment of Etcembly's picomolar affinity bispecific T-cell engager targeting PRAME, ETC-101, has been covered by inside Precision...

25 views

Etcembly announces breakthrough in optimising TCR assets

Etcembly Announces Breakthrough in Optimising TCR Assets. Successful Financing Brings in Singapore VC iGlobe Partners.

317 views

Etcembly Appoints Scott Cuthill as Chief Business Officer

Etcembly Appoints Scott Cuthill as Chief Business Officer. The Oxford based company is transforming TCR immunotherapy research.

452 views

Research Complex at Harwell welcomes Etcembly

Research Complex at Harwell is delighted to welcome Etcembly. The company is continuing to expand to realise its goal to assemble the...

336 views

Etcembly establishes new lab & office space at Oxford Science Park

Immune-focused machine learning firm joins leading AI cohort on Park Etcembly Ltd has moved into more than 1,000 square feet of new...

258 views

Zelluna Immunotherapy AS Announces Exclusive Research Collaboration with Etcembly Limited

Oslo, Norway and Oxford, UK: 29th April 2021. Zelluna Immunotherapy AS announces an exclusive research collaboration with Etcembly Ltd to...

244 views

Oxford-based machine learning start-up Etcembly secures Private Seed Funding

Oxford, UK: 23rd April 2021. No embargo. Etcembly Ltd (Etcembly), a company building a platform to decode immune repertoires in health...

576 views